As a result of the approval of veligrotug by the FDA in June 2026, the Company was required to pay AbbVie, Inc. (formerly ImmunoGen, Inc., “ImmunoGen”) a milestone payment of $10.0 million (see Note 8, Collaborations and License Agreements). The gross carrying amount of the intangible asset is $10.0 million, which is being amortized over approximately 12 years from the approval date. The amount is also included in accrued liabilities in the condensed consolidated balance sheet as of June 30, 2026. The estimated future amortization expense as of June 30, 2026 for the remaining periods in the next five years and thereafter is as follows:


Years Ending December 31	(in thousands)
2026 (remaining)	$	417
2027	833
2028	833
2029	833
2030	833
Thereafter	6,251
Total	$	10,000